MDGL
Price
$327.10
Change
-$7.50 (-2.24%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
7.23B
40 days until earnings call
TRAW
Price
$2.13
Change
-$0.19 (-8.19%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
10.72M
Ad is loading...

MDGL vs TRAW

Header iconMDGL vs TRAW Comparison
Open Charts MDGL vs TRAWBanner chart's image
Madrigal Pharmaceuticals
Price$327.10
Change-$7.50 (-2.24%)
Volume$28.4K
Capitalization7.23B
Traws Pharma
Price$2.13
Change-$0.19 (-8.19%)
Volume$1.39K
Capitalization10.72M
MDGL vs TRAW Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. TRAW commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and TRAW is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (MDGL: $334.60 vs. TRAW: $2.32)
Brand notoriety: MDGL and TRAW are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 71% vs. TRAW: 96%
Market capitalization -- MDGL: $7.23B vs. TRAW: $10.72M
MDGL [@Biotechnology] is valued at $7.23B. TRAW’s [@Biotechnology] market capitalization is $10.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileTRAW’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • TRAW’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than TRAW.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 3 TA indicator(s) are bullish while TRAW’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 3 bullish, 4 bearish.
  • TRAW’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TRAW is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +0.23% price change this week, while TRAW (@Biotechnology) price change was -8.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

MDGL is expected to report earnings on May 13, 2025.

TRAW is expected to report earnings on Nov 14, 2024.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.23B) has a higher market cap than TRAW($10.7M). MDGL YTD gains are higher at: 8.436 vs. TRAW (-73.874). TRAW has higher annual earnings (EBITDA): -24.08M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. TRAW (5.41M). MDGL has higher revenues than TRAW: MDGL (180M) vs TRAW (226K).
MDGLTRAWMDGL / TRAW
Capitalization7.23B10.7M67,607%
EBITDA-450.12M-24.08M1,869%
Gain YTD8.436-73.874-11%
P/E RatioN/AN/A-
Revenue180M226K79,646%
Total Cash926M5.41M17,116%
Total Debt120MN/A-
FUNDAMENTALS RATINGS
MDGL vs TRAW: Fundamental Ratings
MDGL
TRAW
OUTLOOK RATING
1..100
7674
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
28100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4297
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRAW's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for MDGL (70) in the Pharmaceuticals Other industry. This means that TRAW’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for TRAW (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than TRAW’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as TRAW (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to TRAW’s over the last 12 months.

MDGL's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for TRAW (97) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than TRAW’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as TRAW (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to TRAW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLTRAW
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 28 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IJS99.081.46
+1.50%
iShares S&P Small-Cap 600 Value ETF
GXG28.290.24
+0.86%
Global X MSCI Colombia ETF
HAWX33.540.08
+0.25%
iShares Currency Hdgd MSCI ACWI exUS ETF
ACP5.880.01
+0.17%
abrdn Income Credit Strategies Fund
ERY20.29-0.04
-0.20%
Direxion Daily Energy Bear 2X ETF